CLINICAL TRIALS PROFILE FOR CHLORMEZANONE
✉ Email this page to a colleague
All Clinical Trials for chlormezanone
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02582736 ↗ | Antipsychotics and Risk of Hyperglycemic Emergencies | Completed | Canadian Institutes of Health Research (CIHR) | 2012-04-01 | The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs. | |
| NCT02582736 ↗ | Antipsychotics and Risk of Hyperglycemic Emergencies | Completed | Drug Safety and Effectiveness Network, Canada | 2012-04-01 | The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs. | |
| NCT02582736 ↗ | Antipsychotics and Risk of Hyperglycemic Emergencies | Completed | Canadian Network for Observational Drug Effect Studies, CNODES | 2012-04-01 | The purpose of this study is to determine whether the use of atypical antipsychotic medication increases the risk of hospitalization for a hyperglycemic emergency. The investigators will carry out separate population-based cohort studies using administrative health databases in eight jurisdictions in Canada and the UK. Cohort entry will be defined by the initiation of a new antipsychotic medication. Follow-up will continue until hospitalization for a hyperglycemic emergency or the end of 365 days. The results from the separate sites will be combined to provide an overall assessment of the risk of hyperglycemic emergencies among new users of various antipsychotic drugs. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for chlormezanone
Condition Name
Clinical Trial Locations for chlormezanone
Clinical Trial Progress for chlormezanone
Clinical Trial Phase
Clinical Trial Sponsors for chlormezanone
Sponsor Name
| Sponsor Name for chlormezanone | |
| Sponsor | Trials |
| Canadian Institutes of Health Research (CIHR) | 1 |
| Drug Safety and Effectiveness Network, Canada | 1 |
| Canadian Network for Observational Drug Effect Studies, CNODES | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
